Australian Research Peptide Rules Explained
A plain-language look at the regulatory context for research-use peptides in Australia and what labs should verify when sourcing compounds.
Read articleA research-use summary of the scheduling context around Thymosin Beta-4 and what it means for laboratory work.
Australia’s June 2026 Poisons Standard lists Thymosin Beta-4 in Schedule 4 and Appendix D. Find the exact entries, official source and legal limits.
Australia’s June 2026 Poisons Standard marks Thymosin Beta-4 with a # in Schedule 4. The instrument states that substances marked # are also listed in Appendix D. Appendix D section 5 separately names both TB-500 and Thymosin Beta-4.
The Poisons Standard is a federal legislative instrument. It classifies scheduled substances and supplies a model that Australian states and territories implement through their own medicines and poisons laws. It is not a product approval register and it should not be read in isolation when determining whether a particular activity is authorised.
Schedule 4 is headed “Prescription only medicines and prescription animal remedies”. Appendix D identifies additional controls. In the 2026 instrument, section 5 is headed “Poisons for which possession without authority is illegal”. The applicable authority, exemptions, record requirements and supply rules depend on the facts and the legislation in the relevant state or territory.
Labelling a product Research Use Only describes intended use. It does not, by itself, displace the Poisons Standard or state and territory controls. Anyone handling, possessing or supplying a scheduled substance should verify the current instrument and obtain advice specific to their jurisdiction and activity.
The Australian Register of Therapeutic Goods and the Poisons Standard answer different questions. A scheduling entry does not establish that a product is included in the ARTG. Confirm each status from its own official register rather than inferring one from the other.
The scheduling entry and a material’s analytical identity are also separate questions. For the substance terminology and evidence limits, see the TB-500 and Thymosin Beta-4 research reference . The TB-500 10mg batch page publishes the matching analytical record. Neither page changes the legal effect of the current instrument.
This page provides general source-navigation information, not legal advice. The linked federal instrument is the primary source. For in vitro laboratory research purposes only. Not for human or animal consumption.
Links lead to the original paper, DOI record, or open-access full text where available.
This compound is supplied for in vitro laboratory and educational research only. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth). Not for human or animal consumption, therapeutic use, or diagnostic procedures. By purchasing, you confirm you are a qualified researcher or acting on behalf of a licensed research facility, and you assume full responsibility for the safe handling, storage, and lawful use of this compound.
A plain-language look at the regulatory context for research-use peptides in Australia and what labs should verify when sourcing compounds.
Read article
GLOW brings three research peptides together. A careful look at what each component is studied for, and why blend evidence is not the same as single-compound evidence.
Read article
An overview of SS-31, its relationship with cardiolipin in mitochondrial membranes, and how laboratory findings differ from clinical claims.
Read article
The history of DSIP in sleep research, the small human studies that exist, and the limits of the current evidence base.
Read articleTell us what you need. An email address is required so we can reply.